A regimen of a novel bone anabolic medication (which builds bone mass) followed by an antiresorptive agent (which maintains bone mass) has been shown to significantly reduce the risk of fracture among post-menopausal women with severe osteoporosis, according to results of a clinical trial published in The New England Journal of Medicine.
